Tab. 1 List of antibodies used in this study

antigen	fluorophore	reactivity
PVR	APC/Fire™ 750	anti-human
PVRL2	APC	anti-human
Nectin 3	secondary AB	anti-human
Nectin 4	APC	anti-human
GD2	BV510™	anti-human
CD3	PE/Cyanine 7	anti-human
CD3	VioBlue <sup>®</sup>	anti-human
CD56	FITC	anti-human
DNAM-1	BV421™	anti-human
CTLA-4	APC	anti-human
PD-1	BV421™	anti-human
TIGIT	APC/Cyanine 7	anti-human
CD107a	BV421™	anti-human

secondary antibody	fluorophore	clone
goat anti-mouse IgG	APC	Poly4053

isotype control	fluorophore	clone
Mouse IgG1, к Isotype Ctrl	APC/Fire™ 750	MOPC-21
Mouse IgG1, κ Isotype Ctrl	APC	MOPC-21
REA control, human IgG1	APC	REA293
Mouse IgG2a, κ Isotype Ctrl	BV510™	MOPC-173
Mouse IgG1, к Isotype Ctrl	Pe/Cyanine7	MOPC-21
Mouse IgG1, k Isotype Ctrl	BV421™	MOPC-21
Mouse IgG2a, к Isotype Ctrl	APC/Cyanine 7	MOPC-173

Tab. 2 List of guide RNAs

target gene	guide RNA
PVR	GATGTTCGGGTTGCGCGTAG
PVRL2	GATCGGCTGGGCGGTTTAGT
TIGIT	GTCGCTGACCGTGAACGATAC

## **Supplementary Figures**





Fig. S1 Identification of PVR and PVRL2 as potential immune checkpoint molecules
Kaplan-Meier-Curves based on the expression of PVR and PVRL2 in primary NB samples. The curves were
generated with http://r2.amc.nl and RNA Seq data was taken from Zhang et al., 2014.

- a. Overall survival probability with high or low expression of PVR and PVRL2, all tumour stages.
- b. Event-free survival probability and overall survival probability with high or low expression of PVR and PVRL2 in individuals with only high-risk tumours.



**Fig. S2 Expression of GD2 on NB cell lines**Surface expression of GD2 on NB cell lines Kelly, LAN-1, LS, SH-SY5Y, SK-N-AS, SK-N-LO and SH-EP. The surface expression was analysed via flow cytometry.




Fig. S3 Surface expression of TIGIT binding receptors Nectin-3 and Nectin-4
Surface expression of Nectin-3 and Nectin-4 on PVR and PVRL2 wildtype and knockout cell lines SK-N-LO,
SH-EP and LAN-1. The surface expression was analysed via flow cytometry after antibody staining and staining with the corresponding isotype control. Shown is one representable sample from n=3 experiments.




Fig. S4 Identification of PVR/PVRL2 – interaction partners on NK-92 effector cells

- Surface expression of immune checkpoint molecules on primary NK cells and NK-92 cells analysed via flow cytometry. Shown is one representative sample.
- b. Results from all experiments (NK-92 n=3, primary NK cells n=6).
- c. Surface expression of IC molecules after stimulation of pNK cells with IL-2, IL-15 or IL2/IL-15 for 24 hours.





Fig. S5 Generation of TIGIT-/- NK-92, GD2-CAR NK-92 (wildtype) cells and TIGIT-/- GD2-CAR NK-92 cells

- a. Flow cytometry screening of TIGIT on NK-92 cells pre and post knock-out. As controls, unstained samples and samples stained using the corresponding isotype were used.
- b. Schematic representation of the GD2-CAR vector.

antibody stain

c. Surface staining of transduced NK cells on GD2-CAR expression using biotinylated protein L and Streptavidin-APC/Cyanine 7. As controls, the corresponding isotype was used.



PMA/ionomycinK562

unstimulated

Fig. S6 Controls of degranulation assays using NK-92 effector cells and NB cell lines Control assays using unstimulated cells, PMA/ionomycin treated cells and NK-92 co-cultured with K562 (n=3). Error bars showing the standard deviation of triplicates of three assays. p < 0.05, p < 0.01, p < 0.001 or p < 0.001 were indicated by \*, \*\*, \*\*\* or \*\*\*\* respectively.